{
  "docId": "019de075-2cce-7280-b26a-b6cf6a81cc60",
  "docSlug": "0ebab7f84cc526493dad2db7df8c89e5",
  "documentTitle": "MindMed | Investor Day Presentation Deck | 61 slides",
  "authorId": "mindmed",
  "authorName": "MindMed",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 60,
  "pageCount": 61,
  "prevPage": 59,
  "nextPage": 61,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-2cce-7280-b26a-b6cf6a81cc60/60",
  "deckHref": "/decks/019de075-2cce-7280-b26a-b6cf6a81cc60",
  "deckJsonHref": "/decks/019de075-2cce-7280-b26a-b6cf6a81cc60.json",
  "deckAnchorHref": "/decks/019de075-2cce-7280-b26a-b6cf6a81cc60#slide-60",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.05,
        "y": 0.55
      },
      "kind": "list",
      "text": "MM-120 (LSD D-tartrate) for the treatment of GAD and ADHD: Phase 2b dose-optimization study ongoing for GAD; Phase 2a study ongoing for ADHD",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "25af677c-f53b-4855-8eae-5f899347a53a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.85,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "list",
      "text": "A leader in developing psychedelic product candidates to treat brain health disorders; Diversified pipeline of clinical programs; IP and R&D strategies; Leveraging decades of research; Expertise in drug and digital medicine; Expected cash runway through 2025",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3894dd8f-0fa2-4839-8a55-77ca7ac44937",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.05,
        "y": 0.7
      },
      "kind": "list",
      "text": "MM-402 or R(-)-MDMA for the treatment of core symptoms of ASD: IND-enabling studies ongoing; Phase 1 pharmacokinetic/pharmacodynamic trial ongoing",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "80a915be-4244-4566-88e8-44cff831a15b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.25,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Business Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "41491968-fae8-4307-b371-0e6c5870556c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "1d28a62e-9ab5-4091-aac7-7aaf07b46ec0",
      "evidence": "A leader in developing psychedelic product candidates to treat brain health disorders",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}